Fact-checked by Grok 2 weeks ago

Optic neuropathy

Optic neuropathy is a diverse group of disorders characterized by damage to the , the bundle of over one million myelinated nerve fibers that transmits visual signals from the to the , resulting in impaired that can range from mild blurring to severe, permanent loss. This condition arises from multiple etiologies, broadly classified into inflammatory (such as , often linked to demyelinating diseases like ), ischemic (including non-arteritic due to vascular insufficiency), compressive (from tumors or aneurysms), infiltrative (e.g., leukemic involvement), hereditary (like Leber hereditary optic neuropathy caused by mutations), toxic/nutritional (from agents such as ethambutol or , or deficiencies in ), traumatic, radiation-induced, and paraneoplastic types. Symptoms typically include gradual or acute vision loss, dyschromatopsia (impaired ), relative afferent pupillary defect, and visual field abnormalities such as central scotomas, though pain on eye movement is more specific to inflammatory forms like . Diagnosis relies on a detailed , neuro-ophthalmic , and ancillary tests including automated perimetry for field defects, to assess nerve fiber layer thickness, and to identify underlying causes like demyelination or . Treatment strategies are etiology-specific: high-dose intravenous corticosteroids are used for acute inflammatory to hasten recovery, while ischemic forms may require management of vascular risk factors; compressive lesions often necessitate surgical intervention, and toxic cases involve discontinuation of the offending agent. Prognosis varies, with many cases like isolated showing spontaneous improvement in up to 90% of patients, though progression to systemic diseases or bilateral involvement can occur in 15-50% of instances depending on the subtype.

Definition and epidemiology

Definition

Optic neuropathy refers to a group of medical conditions characterized by damage or dysfunction of the , the structure comprising approximately 1.2 million axons of retinal ganglion cells (RGCs) that transmit visual information from the to the . This damage leads to progressive or sudden , often resulting in irreversible vision loss due to the optic nerve's limited capacity for self-repair and regeneration within the . The term encompasses a wide spectrum of etiologies, including ischemic insults (such as nonarteritic anterior ischemic optic neuropathy), inflammatory processes (like ), compressive lesions, toxic exposures (e.g., to or ethambutol), nutritional deficiencies (e.g., ), traumatic injuries, and hereditary disorders (e.g., Leber hereditary optic neuropathy). Pathophysiologically, the common endpoint involves RGC apoptosis, axonal degeneration, and disruption of anterograde and retrograde transport, triggered by mechanisms such as , , , and vascular insufficiency. Unlike peripheral neuropathies, optic neuropathies primarily affect the and are distinguished by their impact on visual function without direct involvement of the sensory . Diagnosis relies on clinical evaluation, including assessment of , , visual fields, and pupillary responses, often supplemented by and electrophysiological tests to identify the underlying cause. While some forms, such as toxic or compressive neuropathies, may respond to targeted interventions if detected early, most lead to optic atrophy and permanent deficits.

Epidemiology

Optic neuropathy refers to a heterogeneous group of disorders characterized by damage to the , leading to variable patterns of . Its is challenging to summarize comprehensively due to the diversity of etiologies, including ischemic, inflammatory, hereditary, compressive, toxic, and nutritional causes, each with distinct incidence, , and demographic profiles. Globally, optic neuropathies collectively contribute to significant visual morbidity, though exact overall figures are limited by underdiagnosis and varying systems. In developed countries, the burden is estimated through subtype-specific studies, with ischemic and inflammatory forms predominating in adults. Nonarteritic anterior ischemic optic neuropathy (NAION) is the most frequent acute optic neuropathy in individuals over 50 years, accounting for a substantial proportion of cases in this demographic. The annual incidence of NAION ranges from 2.3 to 10.2 cases per 100,000 population aged 50 and older, with higher rates observed in those over 50 (up to 10.19 per 100,000). Risk factors include , , , and , which are more prevalent in older adults, contributing to its age-related predominance. NAION shows no significant sex disparity overall, though some studies note a slight predominance in certain cohorts. Inflammatory optic neuropathies, particularly (ON), exhibit an annual incidence of 3 to 6.4 cases per 100,000 person-years in the United States and similar rates (approximately 3.7 per 100,000) in the . Prevalence estimates for ON vary, reaching up to 115 per 100,000 in recent UK data from 2018, with overall US prevalence at 51.6 per 100,000 in 2023. ON disproportionately affects females (incidence ratio up to 3:1 compared to males) and peaks in young adults aged 20 to 40 years, often as an initial manifestation of in 15% to 20% of cases. Geographic variations exist, with higher incidences reported in northern latitudes, potentially linked to environmental or genetic factors associated with demyelinating diseases. Hereditary optic neuropathies, such as (LHON), are rarer mitochondrial disorders with a of approximately 1 in 25,000 to 1 in 45,000 individuals worldwide. LHON primarily impacts young males (mean onset age 25 years), with incomplete leading to visual loss in 50% of male carriers and 10% of female carriers. Compressive optic neuropathies are uncommon, with an incidence of 1.14 to 4 cases per 100,000 per year, often secondary to tumors or trauma. Toxic and nutritional optic neuropathies are even less frequent, with incidences below 1 per 100,000 annually, though outbreaks have occurred, such as the 1992-1993 Cuban epidemic affecting over 50,000 individuals due to nutritional deficiencies. Emerging and debated associations, such as the risk of NAION with certain medications like (with some 2025 studies indicating increased rare risk up to 1 in 10,000 and others decreased risk), highlight evolving epidemiological insights.

Pathophysiology

Mechanisms of damage

Optic neuropathy encompasses a range of conditions that damage the , primarily affecting the axons of retinal ganglion cells (RGCs), which transmit visual information from the to the . This damage often results in axonal degeneration, RGC , and subsequent vision loss, with mechanisms varying by but commonly involving ischemia, , mechanical compression, , or metabolic/toxic insults. Ischemic mechanisms predominate in conditions like non-arteritic anterior ischemic optic neuropathy (NAION), where hypoperfusion of the head leads to , , and axonal swelling. Reduced blood flow disrupts energy metabolism in RGC axons, triggering mitochondrial dysfunction and , ultimately causing irreversible neuronal death. In arteritic forms, such as those associated with , vascular inflammation exacerbates ischemia by occluding the posterior ciliary arteries, leading to edema and rapid vision deterioration. Inflammatory processes, as seen in , involve immune-mediated attacks on the sheath or axons, often linked to demyelinating diseases like . T-cell infiltration and perivascular inflammation cause demyelination, edema, and disruption of axonal conduction, with autoantibodies such as aquaporin-4 IgG in targeting and activating complement cascades for cytotoxic damage. Paraneoplastic optic neuropathy results from autoimmune cross-reactivity, often associated with antibodies like anti-CRMP5, targeting components and causing axonal damage. This leads to multifocal axonal loss and , impairing signal transmission. Mechanical compression, common in tumors or orbital masses, distorts the fibers at sites like the , impeding and inducing secondary ischemia through vascular compromise. Chronic pressure deforms the and activates , contributing to progressive axonal and RGC . Traumatic optic neuropathy typically arises from indirect , such as blunt head , where forces or contusion at the orbital apex cause , hemorrhage, and , disrupting the blood-nerve barrier and leading to . In glaucomatous optic neuropathy, elevated mechanically stresses the lamina cribrosa, blocking axoplasmic flow and causing RGC axonal compression, with vascular dysregulation amplifying ischemic damage in susceptible individuals. Multifactorial elements, including and imbalances, further promote RGC . Toxic and nutritional deficiencies, such as or shortfall, impair mitochondrial function and , resulting in segmental demyelination and distal axonopathy, often reversible if addressed early. Radiation-induced optic neuropathy involves direct damage to cellular DNA, free radical injury, endothelial hyperplasia, and microvascular occlusion, leading to hypoxia, demyelination, and reactive astrocytosis.

Classification

Optic neuropathy is classified anatomically into anterior (involving the optic disc, often with visible swelling or papillitis) and posterior (retrobulbar, without initial disc involvement). This distinction aids in initial evaluation, as anterior forms typically present with optic disc edema, while posterior forms show normal disc appearance acutely. Etiologically, optic neuropathies are broadly categorized based on underlying mechanisms, including ischemic, inflammatory, compressive, toxic/nutritional, infectious, hereditary, traumatic, radiation-induced, paraneoplastic, and infiltrative/neoplastic types. Ischemic optic neuropathy, the most common acute form, results from vascular insufficiency and is subdivided into non-arteritic (NAION, often linked to vascular risk factors like and ) and arteritic (typically due to in older adults). Inflammatory types encompass demyelinating (commonly associated with ) and non-demyelinating forms such as or . Compressive optic neuropathies arise from mass lesions exerting pressure on the optic nerve, such as tumors (e.g., meningiomas or pituitary adenomas) or aneurysms, leading to gradual vision loss. Toxic and nutritional variants stem from exposures or deficiencies, exemplified by causing severe bilateral damage or leading to progressive atrophy. Infectious causes include bacterial (e.g., ), viral (e.g., herpes zoster), or fungal agents, often in immunocompromised individuals. Hereditary forms, like (a mitochondrial disorder causing subacute bilateral vision loss in young males) or autosomal dominant optic atrophy, involve genetic mutations affecting optic nerve structure. Traumatic types result from direct or indirect injury to the optic nerve. Radiation-induced forms occur as a complication of radiotherapy near the optic pathways, involving delayed . Paraneoplastic types are immune-mediated responses associated with underlying malignancies, often preceding cancer . Infiltrative or neoplastic processes, such as leukemic infiltration or , disrupt nerve function through cellular invasion. This multifaceted classification guides diagnostic approaches, with overlap possible in complex cases; for instance, bilateral sequential involvement often suggests toxic, nutritional, or hereditary etiologies over unilateral ischemic or inflammatory ones.

Clinical presentation

Symptoms

Optic neuropathy manifests primarily through disruptions in visual function due to damage to the , with symptoms varying by etiology but commonly including loss and alterations in . The hallmark symptom is reduced , which can range from mild blurring to profound impairment or complete blindness in the affected eye, often developing acutely in inflammatory or ischemic forms and more gradually in compressive or toxic types. This loss is typically unilateral at onset but may become bilateral in hereditary or nutritional deficiencies. Pain is a prominent feature in approximately 90% of cases involving , a common inflammatory subtype, presenting as retro-orbital discomfort exacerbated by eye movements or gaze. In contrast, ischemic and toxic optic neuropathies are often painless, with patients reporting insidious central vision decline. deficits, known as dyschromatopsia, affect most patients, particularly the perception of red hues, which appear desaturated or faded, reflecting early axonal involvement. defects, such as central or cecocentral scotomas, are nearly universal and can be detected via perimetry, while reduced contrast sensitivity contributes to a dimmed or washed-out visual experience. In demyelinating cases, the Uhthoff phenomenon—temporary worsening of vision with heat or exercise—may occur. In pediatric or neuromyelitis optica spectrum disorder-related neuropathies, bilateral involvement may occur more frequently, leading to severe, simultaneous vision loss. Symptoms like photopsias (flashes of light) or may accompany acute presentations, though optic in chronic cases often results in permanent, irreversible deficits without . Overall, the clinical presentation underscores the optic nerve's role in transmitting visual signals, with symptom severity correlating to the extent of axonal loss.

Signs

Optic neuropathy manifests through several objective clinical signs, primarily involving visual function and ocular examination findings. A hallmark sign is the (RAPD), detected via the swinging test, where the affected pupil dilates paradoxically when light is swung to the contralateral eye due to impaired afferent input from the . This occurs in unilateral or asymmetric cases and indicates optic nerve dysfunction, though it may be absent in bilateral symmetric involvement. Visual field defects are a core sign, often identified through perimetry testing, and can include central scotomas, cecocentral defects, arcuate patterns, or altitudinal losses depending on the underlying mechanism. These defects reflect axonal damage along the pathways and are typically irreversible to some degree. Dyschromatopsia, or impaired , is another frequent finding, assessed using Ishihara plates or Farnsworth-Munsell tests, where patients show reduced discrimination, particularly for red-green hues, manifesting as red desaturation on confrontation testing. Ophthalmoscopic examination reveals variable optic disc appearances: in acute phases, optic disc swelling (papilledema) may be present, indicating from , ischemia, or , often accompanied by peripapillary hemorrhages in ischemic forms. In chronic stages, optic atrophy develops, characterized by pallor of the optic disc due to loss of axons. Retrobulbar involvement, common in demyelinating , shows a normal-appearing disc acutely, with atrophy emerging weeks later. Anterior ischemic optic neuropathy frequently presents with sectoral disc and splinter hemorrhages. Additional signs include reduced , often measured via Snellen charts, with profound loss in severe cases, and potential relative preservation of peripheral fields early on. In hereditary forms like Leber hereditary optic neuropathy, peripapillary telangiectasias and disc hyperemia may be observed. These signs collectively guide clinical suspicion and necessitate prompt evaluation to differentiate from other optic pathologies.

Diagnosis

Clinical evaluation

The clinical evaluation of optic neuropathy begins with a detailed patient history to characterize the onset, progression, and associated features of . Acute or subacute unilateral vision loss, often accompanied by exacerbated by eye movements, suggests inflammatory or demyelinating causes such as , while gradual bilateral involvement may indicate toxic, nutritional, or hereditary etiologies. Associated systemic symptoms, such as , jaw claudication, or recent infections, raise suspicion for ischemic or inflammatory processes, and risk factors like , exposure, or family history guide . Red flags including sudden profound vision loss, bilateral simultaneous involvement, or lack of improvement after several weeks warrant urgent assessment to exclude compressive or malignant causes. Ophthalmic examination is central to confirming optic nerve dysfunction. Visual acuity is typically reduced, often asymmetrically, and should be measured using Snellen or LogMAR charts to quantify severity. Color vision testing, such as with Ishihara plates or Farnsworth-Munsell 100-hue test, reveals dyschromatopsia, particularly red-green deficits, which is an early and sensitive indicator of optic neuropathy. Visual field assessment via confrontation testing or formal perimetry identifies characteristic defects, including central/cecocentral scotomas in toxic or demyelinating cases and altitudinal defects in ischemic optic neuropathy. Pupillary examination demonstrates a (RAPD) in unilateral or asymmetric involvement, detected by the swinging flashlight test, signifying optic nerve conduction impairment. Fundus examination via direct or slit-lamp biomicroscopy evaluates the for , swelling ( in anterior forms), or hemorrhages, though findings may be normal in retrobulbar neuropathies. Anterior segment evaluation rules out concurrent ocular pathology, and assessment of eye movements detects motility restrictions in compressive lesions. A comprehensive complements this by identifying involvement, such as in multiple sclerosis-associated , where additional deficits like limb weakness or sensory changes may be present. This stepwise clinical approach establishes the in many cases and informs the need for ancillary investigations.

Ancillary investigations

Ancillary investigations play a crucial role in confirming optic neuropathy, differentiating it from retinal disorders, identifying underlying etiologies, and assessing disease progression or response to . These tests complement clinical by providing objective measures of visual function, structural integrity, and systemic involvement. Selection of investigations depends on the suspected cause, such as inflammatory, ischemic, or compressive mechanisms. Visual field testing, typically performed using automated static perimetry such as Humphrey visual field analysis, quantifies functional deficits in optic neuropathy. Common patterns include central or cecocentral scotomas in demyelinating or toxic neuropathies, altitudinal defects in , and diffuse loss in advanced cases. This test helps localize the lesion and monitor progression, with high sensitivity for detecting subclinical involvement. Electrophysiological studies, including visual evoked potentials (VEP), evaluate the integrity of the visual pathway from retina to cortex. In optic neuropathies, VEP often shows delayed P100 latency, particularly in demyelinating conditions like optic neuritis, aiding early diagnosis even when visual acuity is preserved. Multifocal VEP enhances detection of localized defects and predicts multiple sclerosis risk, complementing the 2024 McDonald criteria which now recognize the optic nerve as a CNS lesion site. Electroretinography (ERG), conversely, is typically normal in pure optic neuropathies but reduced in retinal diseases, helping differentiate the two. Optical coherence tomography (OCT) provides high-resolution imaging of the (RNFL) and ganglion cell layer, quantifying axonal loss in optic neuropathies. Peripapillary RNFL thinning is evident in conditions like or , with average reductions of 20-40% post-acutely, and it tracks recovery or progression over time. Spectral-domain OCT is preferred for its speed and reproducibility in monitoring disc edema resolution. As of the 2024 revision, OCT-measured RNFL thinning in the fellow eye or post- can support fulfillment of dissemination in space for diagnosis. Neuroimaging, primarily (MRI) with gadolinium and fat suppression, is essential for detecting enhancement, , or compressive lesions such as tumors or aneurysms. In unexplained , MRI identifies compressive causes in approximately 20% of cases. Brain MRI can reveal lesions suggestive of in approximately 50-70% of patients at presentation. The presence of one or more such lesions (≥3 mm perpendicular diameter) predicts a 56% 10-year risk of developing MS, compared to 22% in those without lesions (ONTT). Computed (CT) may be used if MRI is contraindicated, particularly for bony abnormalities. Laboratory investigations target specific etiologies based on clinical suspicion. For arteritic , (ESR) and (CRP) levels show combined sensitivity of 99% and specificity of 97% for . Aquaporin-4 antibodies (NMO-IgG) confirm . (MOG) IgG antibodies should also be tested in suspected inflammatory , especially in cases with bilateral involvement, peripapillary hemorrhages, or steroid-resistant disease, to identify MOG antibody-associated disease (MOGAD). Additional tests include antinuclear antibodies (ANA) for autoimmune optic neuropathy, (ACE) for , and syphilis serology (FTA-ABS) when indicated. may reveal in or malignant cells in infiltrative processes. Genetic testing is warranted in suspected hereditary optic neuropathies, such as analysis for mutations (e.g., 11778G>A), confirming in over 95% of familial cases. Fundus autofluorescence can detect as a buried cause of neuropathy through hyperautofluorescent signals.

Causes

Ischemic

Ischemic optic neuropathy (ION) refers to damage resulting from inadequate blood supply, leading to sudden vision loss, and represents one of the most common causes of acute optic neuropathy in adults over 50 years old. The condition arises from ischemia in the 's vascular supply, primarily involving the short posterior ciliary arteries, which can cause of the head or retrobulbar segments. ION is classified into anterior ION (AION), affecting the , and posterior ION (), involving the intraorbital portion behind the lamina cribrosa; AION is further subdivided into arteritic and non-arteritic forms based on underlying . Arteritic anterior ischemic optic neuropathy (AAION) is predominantly caused by (GCA), a that inflames and occludes the short posterior ciliary arteries, leading to thrombotic infarction of the head. This form typically affects individuals over 70 years, with additional risk factors including female sex, Northern European ancestry, and associated systemic symptoms such as , jaw claudication, or . GCA-mediated inflammation disrupts the vessel walls, causing luminal narrowing and ischemia, and AAION often presents bilaterally if untreated, underscoring the need for prompt to prevent contralateral involvement. Non-arteritic anterior ischemic optic neuropathy (NAION) is the most frequent subtype, accounting for the majority of ION cases, and is characterized by transient hypoperfusion of the head without evidence of . Its etiology is multifactorial and often idiopathic, but strongly associated with vascular risk factors including (present in up to 50% of cases), diabetes mellitus (around 25%), , and , which contribute to and reduced . Anatomical predisposition plays a key role, with approximately 97% of patients exhibiting a "disc at risk"—a small, crowded head with a cup-to-disc ratio less than 0.3—potentially leading to compartment syndrome-like ischemia during hypotensive episodes. Other contributing factors include (reported in 71% of cases in some studies), nocturnal , and hypercoagulable states, which exacerbate microvascular compromise. Posterior ischemic optic neuropathy (PION) is rarer and involves ischemia of the retrobulbar , lacking initial disc swelling, and is diagnosed by exclusion after ruling out anterior involvement. Non-arteritic PION often occurs in settings, particularly during prolonged surgeries such as cardiac, spinal, or non-ocular procedures, triggered by factors like significant intraoperative blood loss, , , or extended time, which collectively impair posterior circulation. Arteritic PION can also stem from GCA, mirroring AAION mechanisms but affecting distal segments. Certain medications and procedures heighten risk across ION subtypes; phosphodiesterase-5 inhibitors (e.g., ) are implicated in NAION due to their vasodilatory effects potentially causing systemic and optic nerve hypoperfusion, though evidence remains controversial with mixed study outcomes. use has been linked to increased NAION incidence via vascular toxicity, while or prior ocular surgeries (e.g., extraction) may contribute through mechanical crowding or transient fluctuations. Overall, NAION incidence ranges from 2.3 to 10.3 cases per 100,000 annually in those over 50, highlighting its public health impact primarily among White populations with vasculopathic profiles.

Inflammatory

Inflammatory optic neuropathy refers to damage to the resulting from processes, with being the most common manifestation. This condition involves acute or subacute of the , often leading to demyelination and impaired visual from the to the . It typically affects young adults, with an annual incidence of 1–5 cases per 100,000 population, showing a predominance (up to 77%) and higher prevalence in Caucasians. The primary causes are autoimmune disorders, where immune-mediated targets the sheath or axons of the . Multiple sclerosis (MS) is the most frequent association, with occurring as the initial presentation in approximately 15–20% of MS cases and in up to 50% of patients over their lifetime. (NMOSD), characterized by aquaporin-4 antibody positivity in about 80% of cases, often presents with more severe, bilateral and poorer recovery. antibody-associated disease (MOGAD) represents another demyelinating cause, typically featuring milder, recurrent episodes with better prognosis. , a granulomatous disorder, can cause optic neuropathy through direct nerve infiltration or , often with systemic symptoms like or pulmonary involvement. Infectious etiologies also contribute significantly, particularly in atypical or bilateral presentations. Bacterial infections such as (treated with penicillin) or (ceftriaxone-responsive) induce optic nerve inflammation via direct invasion or immune response. Viral agents, including herpes zoster, , or , can lead to retrobulbar neuritis, often with concurrent systemic infection signs. These infectious forms may mimic autoimmune but require serological confirmation to guide targeted therapy.

Compressive

Compressive optic neuropathy (CON) arises from mechanical compression of the by intrinsic or extrinsic lesions, leading to axonal damage, ischemia, and progressive . This condition can occur anywhere along the optic nerve pathway, from the to the intracranial segments, and is often insidious in onset, distinguishing it from more acute optic neuropathies. The most common etiologies are neoplastic, accounting for approximately 76% of cases in a population-based study, with pituitary adenomas being the leading cause (35% of instances), followed by meningiomas (17%) and intracranial aneurysms (13%). Pituitary adenomas, particularly macroadenomas, compress the , often resulting in bitemporal hemianopia due to involvement of crossing nasal fibers. Meningiomas, such as those arising from the sheath or sphenoid wing, exert direct extrinsic pressure and may encase the nerve, leading to gradual loss. Other neoplastic causes include optic gliomas (prevalent in 3-5% of pediatric tumors) and craniopharyngiomas (incidence of 0.5-2 per 100,000 per year), which can compress the anterior visual pathway. Non-neoplastic causes represent about 24% of cases and include thyroid orbitopathy (also known as ), which has an incidence of 16 per 100,000 in females and 2.9 per 100,000 in males, often due to extraocular muscle enlargement impinging on the within the orbital apex. Additional non-tumorous etiologies encompass orbital pseudotumor (idiopathic orbital inflammation), fibrous dysplasia of the , and vascular anomalies like dolichoectatic arteries. These compressive forces disrupt axoplasmic flow and induce secondary ischemic changes, exacerbating nerve atrophy. The overall incidence of was estimated at 1.14 per 100,000 per year in a population-based study in (2000–2018), with neoplastic forms predominating in adults.

Infiltrative

Infiltrative optic neuropathy refers to a group of disorders characterized by the direct invasion of the or by malignant or, less commonly, inflammatory cells, leading to optic nerve dysfunction. This condition often presents with disc edema, , or a combination, and can mimic other forms of optic neuropathy due to its variable appearance. Common causes include hematologic malignancies such as (ALL), which accounts for approximately 53% of leukemic infiltrative cases, and B-cell , responsible for about 67% of lymphomatous cases. Solid tumors like breast carcinoma and pinealoblastoma can also infiltrate the via direct extension, hematogenous spread, or dissemination. Autopsy studies indicate that optic nerve infiltration occurs in up to 18% of cases and 16% of chronic leukemia cases.

Traumatic

Traumatic optic neuropathy (TON) arises from mechanical injury to the optic nerve due to blunt or penetrating head or ocular trauma, leading to direct or indirect damage that disrupts axonal integrity and visual function. It accounts for visual impairment in 0.7–2.5% of head trauma cases overall, with indirect TON occurring in 0.5–5% of closed head injuries and up to 2.5% of midfacial fractures. Common etiologies include motor vehicle accidents (21–63% of cases), falls (26%), assaults (21%), and iatrogenic injuries during orbital or sinus surgeries. The condition predominantly affects young adult males (79% of cases), with a median age of 31–33.5 years, and about 20–21% of cases occur in pediatric populations. TON is classified into direct and indirect subtypes based on the mechanism of injury. Direct TON results from anatomical disruption of the , such as laceration, transection, or avulsion by bone fragments, projectiles, or penetrating objects, often leading to immediate and severe visual loss with poor recovery potential. This type is less common and typically associated with open globe injuries or orbital fractures penetrating the nerve sheath. Indirect TON, comprising the majority of cases (approximately 71.4% involve the intracanalicular segment), stems from blunt force transmission through soft tissues and bone, generating , compressive, or contusive forces without overt nerve laceration. It frequently occurs in the context of orbital apex or fractures, where the 's fixed position within the bony canal amplifies vulnerability to deceleration injuries, such as those from coup-contrecoup mechanisms in high-impact . Pathophysiologically, TON involves primary mechanical damage—axonal shearing, contusion, or —followed by secondary insults including ischemia, vascular compromise, , , and neuronal . In indirect cases, biomechanical forces propagate along the nerve, causing intraneural hemorrhage and swelling that may exacerbate within the narrow , potentially leading to death if untreated. Experimental models highlight roles for factors like receptor-1 and macrophage-derived oncomodulin in amplifying secondary injury and hindering regeneration. Risk is heightened in patients with severe trauma ( >12), where TON manifests in 0.4% of such cohorts.

Hereditary

Hereditary optic neuropathies encompass a diverse group of genetic disorders characterized by progressive degeneration of the , leading to . These conditions are primarily caused by mutations in genes involved in mitochondrial function, particularly those affecting energy production in cells, which are highly susceptible due to their high metabolic demands. The most prevalent forms include maternally inherited Leber hereditary optic neuropathy (LHON) and autosomal dominant optic atrophy (DOA), with rarer autosomal recessive, X-linked, and syndromic variants. LHON is a mitochondrial resulting from point mutations in (mtDNA), most commonly m.11778G>A in the MT-ND4 gene (accounting for ~70% of cases), m.3460G>A in MT-ND1 (~20%), and m.14484T>C in MT-ND6 (~10-15%). These mutations impair complex I of the , causing energy failure and selective loss of retinal cells in the papillomacular bundle. is strictly maternal, with a of approximately 1 in 30,000 to 50,000 individuals, though carrier frequency can reach 1 in 8,500 in certain populations. Clinical onset typically occurs in young adults (peak at 20-30 years), presenting as sequential, painless subacute central vision loss, more frequently in males (male-to-female ratio ~4-5:1), often triggered by environmental factors like or . DOA, also known as optic atrophy type 1 (OPA1), arises from heterozygous mutations in the nuclear OPA1 gene on 3q29, which encodes a dynamin-related essential for mitochondrial fusion and maintenance of the mitochondrial network. Over 400 mutations have been identified, mostly leading to . This autosomal dominant condition has a prevalence of 1 in 12,000 to 50,000, with insidious onset of bilateral visual loss in (median age 4-6 years), progressing slowly to moderate acuity reduction (typically 20/50 to 20/400). Characteristic findings include temporal pallor, central or centrocecal scotomas, and defects, particularly blue-yellow dyschromatopsia. Some cases involve extraocular features like or due to OPA1's role in other tissues. Rarer autosomal recessive forms include mutations in OPA3, causing 3-methylglutaconic aciduria type III (Costeff syndrome), which features early-onset optic atrophy alongside extrapyramidal and elevated urinary 3-methylglutaconic acid; prevalence is unknown but limited to specific ethnic groups like Iraqi Jews. X-linked optic atrophy (OPA2) is exceptionally rare, mapped to Xp11.4-11.21, but the causative gene remains unidentified, presenting with early-onset vision loss and possible . Syndromic hereditary optic neuropathies integrate optic atrophy with multisystem involvement. Wolfram syndrome (type 1), due to biallelic WFS1 mutations on 4p16.1, is autosomal recessive and manifests as diabetes insipidus, diabetes mellitus, optic atrophy, and deafness (DIDMOAD), with optic nerve degeneration often evident by age 6-8 years and prevalence around 1 in 500,000. Other syndromic examples include OPA3-related disorders with cataracts or spastic paraplegia.

Nutritional

Nutritional optic neuropathy refers to a bilateral, symmetric form of optic nerve damage resulting from deficiencies in essential vitamins or minerals, leading to progressive loss. It is characterized by mitochondrial dysfunction in the , particularly affecting the papillomacular bundle, which results in central or cecocentral scotomas and impaired . This condition is distinct from other optic neuropathies due to its reversible nature when addressed early through nutritional replenishment. The primary causes involve deficiencies in vitamins and other nutrients critical for metabolism. (cobalamin) deficiency is the most common, often stemming from , vegan diets without supplementation, malabsorption syndromes, or gastrointestinal surgeries such as bariatric procedures. (vitamin B9) deficiency frequently co-occurs with B12 shortfall, exacerbated by poor dietary intake, , or increased demands during . (vitamin B1) deficiency is linked to chronic and , while arises post-gastric bypass or excessive supplementation, which inhibits . These deficiencies impair energy production and cause in retinal cells. Risk factors include chronic malnutrition, , which impairs nutrient absorption, and modern dietary trends like strict or ketogenic diets lacking fortified foods. Bariatric surgery patients are particularly vulnerable due to reduced nutrient uptake, with incidence rising in recent decades. Genetic predispositions may amplify susceptibility, though environmental nutritional deficits remain the dominant trigger.

Toxic

Toxic optic neuropathy (TON) refers to damage resulting in caused by exposure to various toxins, typically presenting as bilateral, symmetric vision loss. This condition arises from environmental, occupational, or iatrogenic exposures, with toxins disrupting function through metabolic or direct cytotoxic effects. Common etiologies include ingestion, certain medications, , and solvents, often leading to selective damage of the papillomacular bundle. The primary causes of TON are categorized into alcohols, drugs, heavy metals, and other chemicals. , found in adulterated liquors or , is a notorious agent; ingestion of as little as 4–15 mL can produce , a metabolite that causes severe optic neuropathy and potential blindness. , an antitubercular drug, induces optic neuropathy in 1–2% of treated patients, particularly at doses exceeding 15 mg/kg/day, with effects manifesting after 1–8 months of . Other drugs include (used for resistant infections), which affects up to 30% of long-term users at doses ≥600 mg/day, and , an antiarrhythmic linked to optic neuropathy via phospholipidosis. such as lead cause optic disc edema and thinning, as observed in occupational exposures, while mercury and lead to progressive atrophy. Solvents like and , often from industrial or recreational abuse, contribute through toxic metabolites disrupting . Pathophysiologically, most toxins target mitochondrial function in retinal ganglion cells and optic nerve axons, leading to energy failure and . For instance, methanol's inhibits , halting electron transport and causing acidosis, while ethambutol interferes with copper-dependent enzymes essential for . induce and free radical damage, exacerbating neuronal injury, and some agents like form intralysosomal inclusions that impair cellular . These mechanisms result in selective vulnerability of the optic nerve due to its high metabolic demand and limited vascular redundancy.
Common ToxinKey EffectsExample Reference
Formic acid-induced mitochondrial inhibition; central , blindness
EthambutolDose-dependent optic ; cecocentral
Lead; nerve fiber layer thinning
Reversible axonal damage; vision loss after prolonged use
; optic ,

Paraneoplastic

Paraneoplastic (PON) is a rare immune-mediated form of damage associated with underlying malignancies, resulting from cross-reactive autoantibodies targeting antigens. It typically arises in the context of systemic cancers, most commonly lung cancer (SCLC) and , through mechanisms involving antineuronal antibodies such as anti-collapsin response-mediator protein-5 (CRMP-5). These antibodies trigger apoptotic death of ganglion cells and axons, often accompanied by other paraneoplastic neurologic syndromes. PON occurs in less than 0.01% of cancer patients and is more frequent in smokers or those with autoimmune predispositions.

Radiation-induced

Radiation-induced optic neuropathy (RION) is a delayed complication of radiotherapy to the head, neck, or orbital regions, caused by ischemic damage to the from radiation-induced vascular endothelial injury and . It typically develops 6 months to 3 years after (range: 1 month to 10+ years), following exposure to tumors near the visual pathways, such as pituitary adenomas, meningiomas, or nasopharyngeal carcinomas. Risk factors include total radiation dose exceeding 50–60 , fractionation schedules, concurrent , , and , which exacerbate microvascular compromise and lead to optic nerve . Incidence is rare below 50 (less than 1%) but rises to 5% or higher at doses over 60 .

Management

Acute interventions

Acute interventions for optic neuropathy focus on rapidly addressing the underlying cause to minimize axonal damage and preserve visual function, with strategies varying by such as inflammatory, ischemic, traumatic, or toxic mechanisms. Prompt through clinical evaluation, , and laboratory tests is essential to guide therapy, as delays can lead to irreversible vision loss. Supportive measures, including and monitoring for complications like elevated , are often integrated across types. In inflammatory optic neuropathy, particularly , high-dose intravenous (IVMP) administered at 500–1000 mg/day for 3–5 days remains the cornerstone of acute management, accelerating recovery of and contrast sensitivity without altering long-term outcomes. This approach is evidenced by the Optic Neuritis Treatment (ONTT), which showed faster resolution of symptoms compared to , alongside a reduced risk of development in the first two years. Oral corticosteroids alone (e.g., 1 mg/kg/day) are contraindicated due to an increased risk of early recurrent , as demonstrated in the same trial. For steroid-refractory cases or (NMOSD)-related optic neuritis, initiated within 7 days of onset improves visual recovery rates, with studies reporting better outcomes than steroids alone. Intravenous immunoglobulin (IVIG) may be considered as an adjunct in antibody-associated disease (MOGAD) if initial therapies fail. For ischemic optic neuropathy, acute management prioritizes etiology-specific interventions to prevent progression. In arteritic anterior ischemic optic neuropathy (AAION) associated with , immediate high-dose IV (1 g/day for 3–5 days) followed by oral taper (1 mg/kg/day, gradually reduced based on inflammatory markers like ESR and CRP) is critical to halt vision loss in the affected eye and protect the contralateral eye, reducing systemic complications such as . Steroid-sparing agents like , an IL-6 inhibitor, can be added early in refractory cases to minimize steroid exposure while maintaining efficacy. In non-arteritic anterior ischemic optic neuropathy (NAION), no established acute therapy exists, though limited evidence supports short-term IVMP (500 mg twice daily for 3 days) for modest gains, and (administered within 5 days) has shown improvements in best-corrected and retinal nerve fiber layer thickness in small trials. Posterior ischemic optic neuropathy follows similar neuroprotective approaches, with variable success from high-dose steroids combined with E1. Traumatic optic neuropathy requires urgent assessment for indirect or direct , with interventions aimed at relieving secondary insults like or ischemia. In cases of orbital , immediate surgical —via lateral canthotomy, cantholysis, or bony orbitotomy—is recommended within 2–4 hours to restore and prevent irreversible damage, as ischemia can occur in under . High-dose systemic corticosteroids (e.g., IVMP) are used in some centers but lack supporting evidence from randomized trials and are associated with harm, including increased mortality and disability, per the Corticosteroid Randomisation After Significant () study. Adjunctive therapies like intravenous or may address elevated , though randomized controlled trials (e.g., involving or levodopa-carbidopa) have shown no benefit. In acute toxic optic neuropathies, cessation of the offending agent is paramount, supplemented by targeted . For methanol-induced , emergent administration of or inhibits toxic metabolite formation, while rapidly removes the poison, alongside and to enhance elimination and correct . Adjunctive (10,000 units IV every 12 hours for 3 days) and high-dose IVMP (250 mg every 6 hours) have been recommended in guidelines, showing potential neuroprotective effects in case series. For other toxins like ethambutol, no specific exists beyond immediate discontinuation and supportive care, with visual recovery dependent on exposure duration. Compressive optic neuropathy demands rapid surgical relief of mass effect, such as tumor resection or shunting, to avert progression, particularly in cases like where threatens bilaterally. Infiltrative causes, such as , may require urgent and initiation if acute loss occurs, though evidence is limited to case reports emphasizing speed of intervention.

Long-term care

Long-term care for optic neuropathy emphasizes preservation of residual , prevention of progression or recurrence, and management of underlying etiologies through multidisciplinary approaches involving ophthalmologists, neurologists, and specialists. Regular follow-up examinations are recommended, typically every 3-6 months initially and annually thereafter, depending on the type and stability, to monitor , color , visual fields via perimetry, and structure using (OCT). These assessments help detect subclinical progression, such as retinal nerve fiber layer thinning, which correlates with axonal loss and functional decline. In ischemic optic neuropathy, particularly nonarteritic anterior ischemic optic neuropathy (NAION), long-term strategies focus on modifiable risk factor control to mitigate fellow-eye involvement, which occurs in 15-25% of cases. This includes aggressive management of hypertension, diabetes mellitus, , and through lifestyle modifications, medications like statins or antihypertensives, and . Low-dose aspirin (81 mg daily) is often recommended for its potential antiplatelet effects, though randomized trials show limited impact on visual outcomes. For arteritic forms linked to , prolonged therapy (often tapered over months to years) combined with steroid-sparing immunosuppressants like is standard to prevent systemic complications and further ischemic events. For inflammatory optic neuropathies, such as associated with (MS), (NMOSD), or myelin oligodendrocyte glycoprotein -associated disease (MOGAD), disease-modifying therapies (DMTs) are pivotal for relapse prevention and long-term visual preservation. In MS-related cases, DMTs like , , or monoclonal antibodies (e.g., ocrelizumab) reduce relapse risk by 30-50%. NMOSD requires aquaporin-4 antibody-targeted therapies such as or rituximab to suppress attacks, while MOGAD may involve maintenance with mycophenolate mofetil or intravenous immunoglobulin. Serial brain and orbital MRI, along with antibody testing, guides therapy adjustments. Compressive and infiltrative optic neuropathies necessitate vigilant surveillance of the underlying lesion, such as tumors (e.g., , ) or inflammatory masses, with periodic imaging (MRI every 6-12 months) post-decompression surgery or radiation. For eye disease-related compression, sustained euthyroidism control and teprotumumab infusions may stabilize optic nerve function. Infiltrative cases, like , require ongoing or rituximab monitoring to prevent recurrence. Traumatic optic neuropathy long-term care centers on and , with serial OCT and testing to track axonal recovery. For incomplete injuries, hyperbaric oxygen or may be trialed, though evidence is inconclusive; avoidance of secondary insults like is key. Hereditary forms, exemplified by Leber hereditary optic neuropathy (LHON), involve (900 mg daily) to support mitochondrial function and potentially improve in 20-30% of subacute cases, alongside to prevent transmission. Emerging gene therapies, like AAV2-ND4, show sustained benefits in phase III trials. Nutritional and toxic optic neuropathies require etiology-specific interventions to halt progression and promote recovery. Nutritional deficiencies (e.g., , ) demand lifelong supplementation, with intramuscular B12 (1000 mcg weekly) for states like post-bariatric , achieving stabilization in 70-80% of cases if initiated early. Toxic exposures, such as or ethambutol, mandate immediate cessation and chelation (e.g., for ), followed by B-vitamin replacement; tobacco-alcohol improves with abstinence and balanced nutrition. Across all types, visual rehabilitation is integral, incorporating low-vision aids (e.g., magnifiers, screen readers), for daily activities, and contrast sensitivity training to enhance . Psychological support addresses and adjustment to vision loss, which affects up to 40% of patients. Multidisciplinary care coordination ensures holistic management, with emphasis on to optimize adherence and outcomes.

Prognosis

Outcomes by type

The prognosis for compressive optic neuropathy varies based on the underlying , the extent of axonal damage, and the timeliness of intervention. In cases involving tumoral compression, approximately 60% of patients experience some visual improvement following surgical , with complete possible within one week if performed early. Factors adversely affecting outcomes include severe preoperative visual loss, atrophy, tumor recurrence, and prolonged duration of symptoms exceeding several months. Earlier , particularly for vascular insufficiency rather than irreversible axonal injury, enhances the likelihood of vision restoration, emphasizing the need for prompt . Infiltrative optic neuropathy, often associated with leukemias or lymphomas, generally carries a poor overall , with mean survival after around 16 months across reported cases. Visual is possible with aggressive, timely treatments such as high-dose corticosteroids and , as demonstrated in instances where bilateral vision loss improved to 20/20 acuity following steroid initiation. However, delays in —frequently requiring confirmation—worsen outcomes, and infiltration by or B-cell correlates with higher rates of persistent and systemic mortality, with survival varying by subtype (e.g., 1 month for ). The for ischemic optic neuropathy, such as non-arteritic anterior ischemic optic neuropathy (NAION), is generally guarded, with no proven specific treatment to improve visual outcomes. Initial is often severely reduced, and is variable and typically partial; final acuity is 20/60 or better in about 60% of cases, but significant field loss persists in most. Arteritic forms, like those due to , have a worse if untreated, with up to 20% risk of no light perception, though prompt can preserve vision in the fellow eye. Risk of fellow eye involvement is 15-25% within 5 years, driven by shared vascular factors. Inflammatory optic neuropathy, particularly , has a favorable prognosis, with most patients experiencing significant . In the Optic Neuritis Treatment Trial (ONTT), over 90% achieved of 20/40 or better within 12 months, regardless of , though may take weeks to months. Persistent subtle deficits, such as abnormalities (in ~35% at 5 years) or reduced contrast sensitivity, occur in a minority despite good acuity. Risk of recurrence is 28% within 5 years, and progression to affects 50% at 15 years, potentially leading to further episodes. Traumatic optic neuropathy, particularly the indirect form, presents variable visual outcomes, with final visual acuity primarily predicted by initial presentation; for every 1 logMAR unit worse at onset, final acuity deteriorates by approximately 0.60 logMAR. In a of patients, mean visual acuity improved from 1.61 logMAR (about 20/800) to 1.31 logMAR (about 20/400), representing a 3-line gain, with 61% of eyes better than no light perception showing at least 2-line improvement over 3-6 months. remains guarded for no light perception cases, which often persist unchanged, and is uninfluenced by comorbidities like orbital fractures or treatment modalities such as steroids. Hereditary optic neuropathies, exemplified by Leber hereditary optic neuropathy (LHON), typically yield poor long-term visual outcomes, with most patients remaining severely impaired due to central scotomas and reduced acuity rarely progressing to no light perception. Recovery is limited, occurring in few cases after about , and varies by mitochondrial mutation: the G11778A variant (most common) portends the least favorable prognosis with minimal significant recovery, while T14484C offers the best (37-58% recovery post-nadir), and G3460A an intermediate course. Younger age at onset (typically 10-30 years) correlates with slightly better prospects, whereas late-onset cases linked to or exposure may exacerbate severity. Nutritional optic neuropathy's outcomes hinge on the duration and severity of deficiency, with early supplementation (e.g., B12, ) enabling substantial recovery in many patients, including initial improvements in acuity followed by . Prognosis diminishes markedly if begins more than 3 months after onset, and severe cases (acuity ≤20/400) rarely achieve normal vision, with about 10% experiencing residual loss even after therapy. Historical epidemics, such as the 1991-1993 outbreak, illustrated rapid symptom amelioration post-supplementation, though some deficits persisted, underscoring the reversibility potential when addressed promptly. Toxic optic neuropathy's prognosis is highly dependent on the offending and intervention speed, with most cases reversible upon cessation of exposure and supportive care, though permanent defects occur in untreated or severe instances. For ethambutol-induced toxicity, prompt discontinuation leads to progressive visual over up to 6 months, but presentations with acuity worse than 6/60 predict poorer recovery; methanol poisoning resolves disturbances in 2-3 weeks for most but leaves defects in at least 33%. Tobacco-alcohol and folate deficiencies show good outcomes if addressed within months, while B12 deficiency improves acuity in over 50% with oral , highlighting the importance of early removal to mitigate irreversible damage.

Complications

Optic neuropathy frequently results in permanent damage to the optic nerve, leading to irreversible visual impairments that constitute its primary complications. These include reduced visual acuity, which can persist despite treatment, affecting daily activities such as reading and driving. In cases like optic neuritis, while most patients recover good visual acuity, approximately 35% experience ongoing visual field defects or other subtle deficits such as blurred vision or reduced contrast sensitivity, even after initial recovery phases. Visual field defects, such as altitudinal hemianopia in ischemic forms or central scotomas in toxic and nutritional variants, further compromise peripheral or central vision and often do not resolve fully. Color vision abnormalities, known as dyschromatopsia, are also common and can remain a lifelong issue, impairing the ability to distinguish hues and contributing to reduced quality of life. The involvement of the contralateral eye represents a significant risk, potentially leading to bilateral vision loss and legal blindness in severe instances. In non-arteritic anterior ischemic optic neuropathy (NAION), the fellow eye is affected in 15-25% of cases within five years, often exacerbated by shared vascular risk factors like or . Hereditary forms, such as Leber hereditary optic neuropathy, carry an even higher likelihood of sequential bilateral involvement, with the second eye typically affected within weeks to months, resulting in profound central vision loss. Traumatic optic neuropathy can cause acute, devastating unilateral or bilateral deficits, with incomplete recovery in up to 50% of cases, depending on the injury's severity. Over time, untreated or progressive optic neuropathy often culminates in optic atrophy, characterized by pallor of the optic disc and axonal degeneration, signaling irreversible neuronal loss. This end-stage complication amplifies visual decline and is observable via fundus examination or optical coherence tomography. Infiltrative or compressive types may additionally lead to secondary glaucoma due to elevated intraocular pressure from nerve swelling, further threatening remaining vision. While visual complications predominate, certain etiologies introduce systemic risks; for example, arteritic forms associated with giant cell arteritis can precipitate cerebrovascular events if the underlying vasculitis is not addressed promptly. Overall, early intervention is crucial to mitigate these cascading effects and preserve functional vision.

References

  1. [1]
    Clinical approach to optic neuropathies - PMC - PubMed Central
    Optic neuropathy can be caused by demyelination, inflammation, ischemia, infiltration, compression, and hereditary and toxic/nutritional causes.
  2. [2]
    Optic Neuritis and Neuropathy: Background, Etiology, Pathophysiology
    Oct 1, 2025 · Optic neuritis (ON) is a demyelinating inflammation of the optic nerve that typically first occurs in young adulthood (see the image below).Missing: authoritative sources
  3. [3]
    Neuro-protection and Neuro-regeneration of the Optic Nerve
    May 26, 2021 · Optic neuropathies refer to a collection of diseases in which retinal ganglion cells (RGCs), the specialized neuron of the retina whose axons ...Missing: authoritative | Show results with:authoritative
  4. [4]
    Optic Neuropathy - an overview | ScienceDirect Topics
    Optic neuropathy is a neurodegenerative disease characterized by damage to the optic nerve, resulting in visual impairment.
  5. [5]
    Optic Neuropathies: Current and Future Strategies for Optic Nerve ...
    Apr 10, 2023 · Optic neuritis is an inflammatory condition involving the optic nerve and is the most common acute optic neuropathy in young adults. Optic ...Missing: definition symptoms<|control11|><|separator|>
  6. [6]
    Ischemic Optic Neuropathy: What It Is, Symptoms & Treatment
    Ischemic optic neuropathy (ION) is when you have sudden vision loss or changes because your optic nerves aren't getting enough blood flow.
  7. [7]
    Understanding mechanisms of pressure-induced optic nerve damage
    It is clear that chronic pressure-induced optic nerve damage involves cellular changes in both the optic nerve head and retina.
  8. [8]
    A Systematic Literature Review on Traumatic Optic Neuropathy - 2021
    Feb 26, 2021 · Another mechanism that is thought to be involved in TON is diffuse axonal injury. Detrimental inertial forces to the head cause diffuse axonal ...<|control11|><|separator|>
  9. [9]
    Mechanisms of optic nerve damage in primary open angle glaucoma
    The etiology of POAG is likely to be multifactorial. Mechanical, vascular and other factors may influence individual susceptibility to optic nerve damage.
  10. [10]
    [PDF] Approach to Optic Neuropathies - Brigham and Women's Hospital
    This review presents a rational approach to the evaluation of an optic neuropathy, with a focus on conducting a history and examination, establishing a.
  11. [11]
    Approach to diagnosis and management of optic neuropathy
    Causes of optic neuropathy may be broadly divided into inflammatory, infective, ischemic, toxic, metabolic, and heriditary [Table 1]. T1-3 Table 1:.
  12. [12]
    Optic Neuritis - StatPearls - NCBI Bookshelf - NIH
    Jan 20, 2025 · Optic neuritis is a vision-threatening disorder and often the first symptom of demyelinating diseases such as multiple sclerosis.
  13. [13]
    Optic Neuritis: Symptoms, Causes & Treatment Options
    Optic neuritis is a condition that can cause pain and vision loss. It often happens in connection with chronic autoimmune or inflammatory conditions.
  14. [14]
    Diagnosis and clinical features of common optic neuropathies
    Disorders of the optic nerves (optic neuropathies) are some of the most common causes of visual loss, and can present in isolation or with associated ...Missing: definition | Show results with:definition
  15. [15]
    Optic Ischemia - StatPearls - NCBI Bookshelf
    May 6, 2024 · Optic ischemia is a severe condition threatening vision integrity by causing ischemic damage along the optic nerve's intricate pathway.Missing: definition | Show results with:definition<|control11|><|separator|>
  16. [16]
    Clinical Overview of Leber Hereditary Optic Neuropathy - PMC
    Patients are usually asymptomatic until they develop visual disturbance in the central visual field in the first eye (acute phase). Similar symptoms appear in ...<|control11|><|separator|>
  17. [17]
  18. [18]
    Clinical approach to optic neuritis: pitfalls, red flags and differential ...
    We discuss the differential diagnosis of ON and clinical red flags that require careful diagnostic assessment of other diseases.
  19. [19]
    Evaluation and Management of Isolated Optic Atrophy
    Apr 1, 2007 · Ancillary Testing. Computerized automated perimetry may detect specific patterns of visual loss helpful in the differential diagnosis.
  20. [20]
    Ancillary Testing Commonly Used in Neuro-ophthalmology 1
    Jan 9, 2019 · Electrophysiologic testing can help differentiate retinal from optic nerve disease in selected cases. ... diagnosis of optic neuropathy. Visual ...<|control11|><|separator|>
  21. [21]
    Ischemic Optic Neuropathies: Current Concepts - PMC
    Ischemic optic neuropathy (ION) is the term ascribed to optic nerve disease that is the result of a transient or permanent interruption of the blood supply.
  22. [22]
    Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) - EyeWiki
    Disease. Ischemia of the optic nerve can occur in different anatomical locations and can have myriad etiologies. It is helpful to classify these syndromes ...
  23. [23]
    NAION: Diagnosis and Management
    Aug 1, 2022 · In the United States, the estimated annual incidence of NAION ranges from 2.3 to 10.2/100,000 for the population over 50 years old and 0.54/ ...
  24. [24]
    Inflammatory Optic Neuropathies - PMC - PubMed Central - NIH
    The aim of this review is to highlight the clinical presentation of a variety of inflammatory optic neuropathies through a case-based format.
  25. [25]
    The Diagnosis and Treatment of Optic Neuritis - PMC
    The diagnosis of optic neuritis is based on a constellation of symptoms and signs. The onset is usually with pain on eye movement in one eye and subacute visual ...
  26. [26]
    Compressive Optic Neuropathy - StatPearls - NCBI Bookshelf - NIH
    Compressive optic neuropathy can be caused by intrinsic or extrinsic compression anywhere along the optic nerve.Missing: definition | Show results with:definition
  27. [27]
    Compressive Optic Neuropathy - Eye Disorders - Merck Manuals
    Etiology of Compressive Optic Neuropathy​​ Compressive optic neuropathy is often caused by a tumor, such as an orbital or pituitary tumor (1). Inflammation (such ...
  28. [28]
  29. [29]
    Infiltrative Optic Neuropathies: Opening Doors to Sinister Pathologies
    May 8, 2017 · Disc edema, optic nerve dysfunction and a normal appearing disc in any combination may occur in infiltrative optic neuropathies.
  30. [30]
    Optic neuropathy in the context of leukemia or lymphoma
    If infiltration is obvious, treatment can be immediately initiated, potentially involving orbital radiation and/or induction chemotherapy with the goal of ...
  31. [31]
    Infiltrative Optic Neuropathy in Advanced Breast Carcinoma - PMC
    Dec 23, 2023 · Infiltrative optic neuropathy is a condition characterized by the invasion of tumor cells into the optic nerve. Breast carcinoma can metastasize ...
  32. [32]
    A Systematic Literature Review on Traumatic Optic Neuropathy - PMC
    Feb 26, 2021 · TON is an unusual cause of visual impairment after blunt or penetrating head trauma. The overall incidence of TON is 0.7–2.5% [8–11]. Indirect ...
  33. [33]
    Traumatic Optic Neuropathy: A Review - PMC - PubMed Central
    The aim of this article is to evaluate current literature on investigation and management of traumatic optic neuropathy (TON), propose recommendations for ...
  34. [34]
    Traumatic optic neuropathy—Clinical features and management ...
    Traumatic optic neuropathy (TON) is an uncommon cause of visual loss following blunt or penetrating head trauma, but the consequences can be devastating.
  35. [35]
    Hereditary Optic Neuropathies: A Systematic Review on the ...
    Jan 3, 2024 · Leber Hereditary Optic Neuropathy (LHON) is one of the most commonly associated mitochondrial diseases with bilateral optic neuropathy [24], ...
  36. [36]
    Hereditary optic neuropathies - PubMed - NIH
    Conclusion: The most common hereditary optic neuropathies are autosomal dominant optic atrophy (Kjer's disease) and maternally inherited Leber's hereditary ...
  37. [37]
    Leber Hereditary Optic Neuropathy - GeneReviews® - NCBI Bookshelf
    Oct 26, 2000 · Leber hereditary optic neuropathy (LHON) typically presents in young adults as bilateral, painless, subacute visual failure.Diagnosis · Clinical Characteristics · Management · Genetic Counseling
  38. [38]
    Genetic Spectrum and Characteristics of Hereditary Optic ...
    Autosomal dominant optic atrophy (ADOA) and Leber hereditary optic neuropathy (LHON) are the most common forms, with a prevalence of 1 in 30,000 to 1 in 50,000 ...
  39. [39]
  40. [40]
    OPA1 Dominant Optic Atrophy: Pathogenesis and Therapeutic Targets
    DOA caused by OPA1 variants is the commonest inherited optic neuropathy in the general population, resulting in progressive blindness in children and young ...
  41. [41]
    Molecular Genetic Basis of Primary Inherited Optic Neuropathies
    A gene for recessive optic atrophy (OPA3) has also been identified. X-linked optic atrophy (OPA2) has been mapped but to date no gene has been identified.
  42. [42]
    Clinical utility gene card for: inherited optic neuropathies including ...
    Aug 24, 2018 · Inherited optic neuropathies can be caused by mitochondrial DNA (mtDNA) variants as in Leber hereditary optic neuropathy (Table 1) or by variants in nuclear- ...
  43. [43]
    WFS1 Spectrum Disorder - GeneReviews® - NCBI Bookshelf - NIH
    Feb 24, 2009 · Identification of p.A684V missense mutation in the WFS1 gene as a frequent cause of autosomal dominant optic atrophy and hearing impairment.
  44. [44]
    Nutritional Optic Neuropathies: State of the Art and Emerging ...
    Aug 31, 2020 · The mainstay of treatment of nutritional optic neuropathy is the supplementation therapy, which is demonstrated to be very effective. Thus, it ...
  45. [45]
    Toxic and Nutritional Optic Neuropathy - StatPearls - NCBI Bookshelf
    Treatment / Management. Treatment of the nutritional or toxic optic neuropathy is based on the cause. Nutritional supplements will need to be given in cases ...Etiology · History and Physical · Treatment / Management · Differential Diagnosis
  46. [46]
    Toxic and Nutritional Optic Neuropathies—An Updated Mini-Review
    Mar 6, 2022 · Nutritional deficiency and genetic factors may make the patient more susceptible to optic neuropathy. A deficiency of nutrients such as ...
  47. [47]
    Treatment and Outcomes in Nutritional Optic Neuropathy - PubMed
    Feb 7, 2019 · The mainstay of treatment for nutritional optic neuropathy involves identifying and replacing deficient nutrients as well as identifying and eliminating ...Missing: symptoms | Show results with:symptoms
  48. [48]
    Toxic Optic Neuropathy - EyeWiki
    Apr 23, 2025 · Toxic optic neuropathy (TON) refers to visual impairment due to optic nerve damage caused by a toxin.Disease Entity · Etiology · Pathophysiology · Diagnosis
  49. [49]
    Toxic optic neuropathies: an updated review - Wiley Online Library
    Aug 27, 2014 · Toxic optic neuropathy (TON) is caused by the damage to the optic nerve through different toxins, including drugs, metals, organic solvents, methanol and ...Examination · Physical Examination · Drugs and Toxic Optic... · Other Drugs
  50. [50]
    Optic neuritis: a comprehensive review of current therapies and ...
    Jun 18, 2025 · This review provides a focused overview of current therapies for demyelinating optic neuritis associated with MS, NMOSD, and MOGAD.
  51. [51]
    Management of ischemic optic neuropathies - PMC - PubMed Central
    Misconception: Steroid therapy can be stopped after 1–2 years because the disease burns itself out. Reality: This is not true at all. The vast majority of ...
  52. [52]
    Anterior Ischemic Optic Neuropathy (AION) Treatment & Management
    Dec 9, 2024 · Once temporal arteritis has been ruled out, continuing is unnecessary because the long-term complications of steroids are considerable.
  53. [53]
    Long-term Efficacy of Orbital Decompression for Compressive Optic ...
    In a retrospective evaluation of the long-term effect of transantralethmoidal decompression for compressive optic neuropathy, the authors evaluated visual ...Missing: care | Show results with:care
  54. [54]
    Leber Hereditary Optic Neuropathy (LHON) - StatPearls - NCBI - NIH
    Management includes lifestyle adjustments, vitamin supplements, and the use of idebenone in the subacute phase, aiming for vision recovery. However, most cases ...
  55. [55]
    Long-term safety of idebenone in patients with Leber hereditary ...
    Results from this long-term real world study therefore confirm that idebenone is well-tolerated in patients with LHON when used in routine clinical practise.
  56. [56]
    Traumatic optic neuropathy management: a systematic review - PMC
    Jun 11, 2024 · Initial treatment should be immediate lateral superior and inferior canthotomy and cantholysis, and simultaneous administration of intravenous ...Traumatic Brain Injury (tbi) · Visual Loss Associated With... · Acute Visual Loss After Tbi
  57. [57]
    Nutritional Optic Neuropathy - EyeWiki
    Long-term and lifelong replacement should be offered to all patients undergoing bariatric surgery or in patients with intestinal malabsorption. Patients who ...
  58. [58]
    Toxic optic neuropathy - Indian Journal of Ophthalmology
    Optic neuropathy may result from exposure to a neuro-poisonous substances toxin in the environment, ingestion of certain foods or other materials containing ...Missing: review | Show results with:review
  59. [59]
    Prognosticators of Visual Acuity after Indirect Traumatic Optic ... - NIH
    Patients with indirect TON (iTON) have more variable visual prognoses, ranging from 20/20 to no light perception (NLP), with stable VA taking 3-6 months to ...
  60. [60]
    Leber Hereditary Optic Neuropathy - EyeWiki
    Jun 13, 2025 · Leber hereditary optic neuropathy (LHON) is the most common inherited mitochondrial disorder. It usually begins as a unilateral progressive ...Missing: care | Show results with:care
  61. [61]
    Optic neuritis - Symptoms & causes - Mayo Clinic
    It's believed to develop when the immune system mistakenly targets the substance covering your optic nerve, resulting in inflammation and damage to the myelin.Overview · Symptoms · When to see a doctor · Causes
  62. [62]
    Nonarteritic Anterior Ischemic Optic Neuropathy - StatPearls - NCBI
    Nonarteritic anterior ischemic optic neuropathy represents one of the most common causes of acute optic nerve–related vision loss in individuals older than 50.Missing: authoritative | Show results with:authoritative
  63. [63]
    Leber hereditary optic neuropathy: MedlinePlus Genetics
    Dec 1, 2013 · Over time, vision in both eyes worsens with a severe loss of sharpness (visual acuity) and color vision. This condition mainly affects central ...
  64. [64]
    Optic Atrophy - StatPearls - NCBI Bookshelf - NIH
    Mar 1, 2024 · Optic atrophy is a pathological term referring to optic nerve shrinkage caused by the degeneration of retinal ganglion cell (RGC) axons.<|separator|>
  65. [65]
    Arteritic Anterior Ischemic Optic Neuropathy (AAION) - EyeWiki
    Arteritic anterior ischemic optic neuropathy (AAION) is an acute, often painful optic neuropathy that occurs predominantly in elderly patients over age 50, ...